caa a22 4500 445882824 CHVBK 20180317145549.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10157-011-0502-5 doi (NATIONALLICENCE)springer-10.1007/s10157-011-0502-5 Diseases of the parathyroid gland in chronic kidney disease [Elektronische Daten] [Hirotaka Komaba, Takatoshi Kakuta, Masafumi Fukagawa] During the past few years, remarkable advances have been made in the understanding and the management of parathyroid diseases in patients with chronic kidney disease (CKD). One of the important insights is the identification of fibroblastic growth factor 23, which has greatly reshaped our understanding of secondary hyperparathyroidism (SHPT). The recent introduction of calcimimetic cinacalcet hydrochloride has led to a major breakthrough in the management of SHPT. Recognition of circulating molecular forms of parathyroid hormone (PTH) is also a major milestone in the accurate assessment of parathyroid function in CKD. Primary hyperparathyroidism should also be considered in patients with CKD, because it can cause various renal manifestations and can also occur as a sporadic disease in these patients. Hypoparathyroidism is occasionally seen in dialysis patients in the setting of diabetes mellitus and malnutrition-inflammation complex syndrome, as well as after parathyroidectomy for advanced SHPT. For patients with adynamic bone disease due to hypoparathyroidism and/or skeletal resistance to PTH, teriparatide, a PTH analog, may have potential for improving bone metabolism and reducing the risk of fracture. In this review, we summarize our current knowledge on diseases of the parathyroid gland in CKD patients, with a particular focus on recent work in the field. Japanese Society of Nephrology, 2011 Chronic kidney disease nationallicence Fibroblast growth factor 23 nationallicence Hypoparathyroidism nationallicence Parathyroid hormone nationallicence Primary hyperparathyroidism nationallicence Secondary hyperparathyroidism nationallicence Komaba Hirotaka Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut Kakuta Takatoshi Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut Fukagawa Masafumi Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 797-809 1342-1751 15:6<797 2011 15 10157 https://doi.org/10.1007/s10157-011-0502-5 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0502-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Komaba Hirotaka Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut NATIONALLICENCE 700 1- Kakuta Takatoshi Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut NATIONALLICENCE 700 1- Fukagawa Masafumi Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-Kasuya, 259-1193, Isehara, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 797-809 1342-1751 15:6<797 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer